Schrodinger Inc
NASDAQ:SDGR

Watchlist Manager
Schrodinger Inc Logo
Schrodinger Inc
NASDAQ:SDGR
Watchlist
Price: 20.84 USD 2.32% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Schrodinger Inc?
Write Note

Schrodinger Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Schrodinger Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Schrodinger Inc
NASDAQ:SDGR
Accrued Liabilities
$58.1m
CAGR 3-Years
41%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Accrued Liabilities
$80.1m
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
18%
Inspire Medical Systems Inc
NYSE:INSP
Accrued Liabilities
$37.5m
CAGR 3-Years
29%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Accrued Liabilities
$25.9m
CAGR 3-Years
14%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Accrued Liabilities
$177.6m
CAGR 3-Years
9%
CAGR 5-Years
16%
CAGR 10-Years
23%
W
Waystar Holding Corp
NASDAQ:WAY
Accrued Liabilities
$29.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Schrodinger Inc
Glance View

Market Cap
1.5B USD
Industry
Health Care

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 664 full-time employees. The company went IPO on 2020-02-06. The firm operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. The Company’s physics-based software platform enables discovery of molecules for drug development and materials applications. Its software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company’s pipeline includes CDC7, Wee1, MALT1, HIF-2 alpha and SOS1/KRAS. Its CDC7 is a small molecule inhibitor for treatment of solid and liquid tumors.

SDGR Intrinsic Value
14.65 USD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is Schrodinger Inc's Accrued Liabilities?
Accrued Liabilities
58.1m USD

Based on the financial report for Sep 30, 2024, Schrodinger Inc's Accrued Liabilities amounts to 58.1m USD.

What is Schrodinger Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
32%

Over the last year, the Accrued Liabilities growth was 16%. The average annual Accrued Liabilities growth rates for Schrodinger Inc have been 41% over the past three years , 32% over the past five years .

Back to Top